Results 81 to 90 of about 3,046 (215)

Mavacamten stabilizes the auto-inhibited state of two-headed cardiac myosin

, 2018
We used transient biochemical and structural kinetics to elucidate the molecular mechanism of mavacamten, an allosteric cardiac myosin inhibitor and prospective treatment for hypertrophic cardiomyopathy.
John A. Rohde, David D. Thomas, Joseph M. Muretta   +2 more
core   +1 more source

Characterization of mavacamten pharmacokinetics in patients with hypertrophic cardiomyopathy to inform dose titration

CPT: Pharmacometrics & Systems Pharmacology
Mavacamten is a selective, allosteric, reversible cardiac myosin inhibitor that has been developed for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
Peter Chang, Vidya Perera, David H. Salinger, Samira Merali, Neelima Thanneer, Hyunmoon Back, Julie D. Seroogy, Daniel D. Gretler, Amy J. Sehnert, Maria Palmisano, Amit Roy   +10 more
doaj   +1 more source

Electrophysiological Substrate and Ablation Outcomes in Atrial Fibrillation With Hypertrophic Cardiomyopathy: A Propensity‐Matched Multicenter Study

Journal of Arrhythmia, Volume 42, Issue 3, June 2026.
Multicentre retrospective propensity‐score‐matched cohort study (n = 286; 3 centres, Pakistan; 2015‐2023) comparing electrophysiological substrate and 12‐month ablation outcomes in patients with atrial fibrillation and hypertrophic cardiomyopathy (HCM‐AF, red) versus lone atrial fibrillation (Lone AF, green; 1:1 PSM on 14 covariates).
Umair Abrar, Fazal Ghaffar, Muhammad Zuhaid, Huzaifa Bin Afzaal, Palwasha Abbasi, Muhammad Hasnain Iqbal, Moʻminov Jahongir Zokirjon oʻgʻli, Sifat Ullah Safi   +7 more
wiley   +1 more source

A Systematic Review and Meta-analysis of Efficacy and Safety of Mavacamten for the Treatment of Hypertrophic Cardiomyopathy

Reviews in Cardiovascular Medicine
Background: Hypertrophic cardiomyopathy (HCM) is a common hereditary cardiomyopathy. Mavacamten, a first-in-class cardiac myosin inhibitor, is considered to be a specific drug for the treatment of HCM.
Li Zheng, Xiaotong Gu, Yumiao Chen, Deping Liu   +3 more
doaj   +1 more source

Atrial cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 727-729, April 2025.
Wojciech Kosmala, Monika Przewłocka‐Kosmala   +1 more
wiley   +1 more source

Towards a Quantitative Understanding of Aficamten Clinical Pharmacology: Pharmacokinetic‐Cardiodynamic Modeling to Support Safety and Efficacy

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 5, May 2026.
ABSTRACT In the phase 3 study SEQUOIA‐HCM (NCT05186818), aficamten, a next‐in‐class cardiac myosin inhibitor, was safe and efficacious in participants with obstructive hypertrophic cardiomyopathy (oHCM). Using pharmacokinetics/pharmacodynamics (PKPD) modeling, we quantified the relationship between aficamten exposure and cardiodynamic measures of ...
Justin D. Lutz, Russ Wada, Daniel L. Jacoby, Stephen B. Heitner, Stuart Kupfer, Polina German   +5 more
wiley   +1 more source

Mavacamten-Associated Temporal Changes in Left Atrial Function in Obstructive HCM: Insights From the VALOR-HCM Trial.

JACC Cardiovascular Imaging
BACKGROUND In severely symptomatic patients with obstructive hypertrophic cardiomyopathy (HCM), the VALOR-HCM (A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy)
M. Desai, Y. Okushi, K. Wolski, J. Geske, Anjali Owens, S. Saberi, Andrew Wang, Paul C. Cremer, M. Sherrid, N. Lakdawala, A. Tower-Rader, D. Fermin, S. Naidu, K. Lampl, A. Sehnert, Steven E. Nissen, Z. Popović   +16 more
semanticscholar   +1 more source

Limited Visibility and Perception of the Clinical Relevance of Clopidogrel Pharmacogenetics in Cardiology Literature

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Clopidogrel is an antiplatelet agent widely utilized in cardiology. It is a prodrug activated in the liver by the cytochrome P450 isoform CYP2C19. Variability in the CYPC2C19 gene influences the activation and efficacy of clopidogrel. This is covered in guidelines from the Clinical Pharmacogenetics Implementation Consortium, the Dutch ...
Cinzia Dello Russo, Luigi Venetucci, Abisope Akintola, Dimitri Gagliardi, Ronnie Ramlogan, Munir Pirmohamed   +5 more
wiley   +1 more source

Transcriptional and functional effects of mavacamten in multiple porcine and human models with hypertrophic cardiomyopathy

British Journal of Pharmacology, Volume 183, Issue 5, Page 1122-1139, March 2026.
Abstract Background and Purpose Mavacamten (MAVA) is a novel small molecule inhibitor of cardiac myosin, mitigating cardiomyocyte hypercontractility in patients with hypertrophic obstructive cardiomyopathy (HOCM). Despite its recent approval for clinical use, the transcriptional and functional impacts of MAVA remain not well understood.
Elisa Kiselev, Wilson Agyapong, Bjarne Jürgens, Elisa Mohr, Shambhabi Chatterjee, Hannah J. Hunkler, Jawad Salman, Giuseppe Cipriano, Marco Bentele, Junqing Liu, Jonas Specht, Kaja S. Menge, Florian J. G. Waleczek, Jonas A. Haas, Anselm A. Derda, Kristina Sonnenschein, Anika Gietz, Susanne Neumüller, Angelika Pfanne, Oliver Beetz, Michael Pflaum, Bettina Wiegmann, Yiangos Psaras, Christopher Toepfer, Robert Zweigerdt, Ante Radocaj, Theresia Kraft, Andre Zeug, Evgeni Ponimaskin, Wilhelm Korte, Alexander Horke, Arjang Ruhparwar, Maximilian Fuchs, Ke Xiao, Christian Bär, Natalie Weber, Thomas Thum   +36 more
wiley   +1 more source

Managing drug–drug interactions with mavacamten: A focus on combined use of antiarrhythmic drugs and anticoagulants [PDF]

Mavacamten is a selective, allosteric, and reversible cardiac myosin inhibitor, representing the first disease-specific treatment for obstructive hypertrophic cardiomyopathy (HCM) that targets the core pathophysiological mechanism of this condition ...
Molinari, Lorenzo V., Mansour, Davide,, Renda, Giulia, Mansour, Davide, Ricci, Fabrizio, Ricci, Fabrizio,, Luzum, Jasmine A., Khanji, Mohammed Y., Olivotto, Iacopo,, Chahal, Anwar A., Molinari, Lorenzo V.,, Renda, Giulia,, Gallina, Sabina,, Vagnarelli, Fabio, Galanti, Kristian, Luzum, Jasmine A.,, Chahal, Anwar A.,, Galanti, Kristian,, Vagnarelli, Fabio,, Gallina, Sabina, Owens, Anjali, Khanji, Mohammed Y.,, Lund University., Owens, Anjali,, Olivotto, Iacopo   +24 more
core   +1 more source